Clinical response does not correlate with intestinal or blood cyclosporine concentrations in patients with Crohn's disease treated with high-dose oral cyclosporine

American Journal of Gastroenterology

Volumn 91, Issue 1, 1996, Pages 37-43

  Sandborn, William J ^b   Tremaine, William J ^b   Lawson, George M ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; MESALAZINE; METHOTREXATE; OLSALAZINE;

ADULT; ARTICLE; CLINICAL ARTICLE; COLONOSCOPY; CROHN DISEASE; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG TISSUE LEVEL; FEMALE; HUMAN; MALE; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PERONEUS NERVE PARALYSIS; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BIOPSY; CROHN DISEASE; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL MUCOSA; INTESTINES; MALE; MIDDLE AGED; REMISSION INDUCTION; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 0030065993     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Feagan BG, McDonald JWD, Rochon J, et al., for the Canadian Crohn's Relapse Prevention Trial Investigators. Low-dose cyclosporine for the treatment of Crohn's disease. N Engl J Med 1994;330: 1846-51.
2. Jewell DP, Lennard-Jones JE, and the Cyclosporin Study Group of Great Britain and Ireland. Oral cyclosporin for chronic active Crohn's disease: A multicentre controlled trial. Eur J Gastroenterol Hepatol 1994;6:499-505.
3. Stange EF, Modigliani R, Penna AS, et al., and the European Study Group. European trial of cyclosporine in chronic active Crohn's disease: A 12 month study. Gastroenterology 1995;109:776-82.
4. Brynskov J, Freund L, Rasmussen SN, et al. A placebo-controlled double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med 1989;321:845-50.
5. Brynskov J, Freund L, Rasmussen SN, et al. Final report on a placebo-controlled, double-blind, randomized trial of cyclosporin treatment in active chronic Crohn's disease. Scand J Gastroenterol 1991;26:689-95.
6. Allam BF, Tillman JE, Thompson TJ, et al. Effective intravenous cyclosporin therapy in a patient with severe Crohn's disease on parenteral nutrition. Gut 1987;28:1166-9.
7. Allison MC, Pounder RE. Cyclosporin for Crohn's disease. Lancet 1984;1:902-3.
8. Bianchi PA, Mondelli M, Quarto Di Palo F, et al. Cyclosporin for Crohn's disease. Lancet 1984;1:1242.
9. Dannecker G, Malchow H, Niessen KH, et al. Morbus Crohn: Erste erfahrungen mit cyclosporin A bei einer adoleszenten. Dtsch Med Wochenschr 1985;110:339-43.
10. Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula in Crohn's disease. Dig Dis Sci 1994;39:374-80.
11. Allison MC, Pounder RE. Cyclosporin for Crohn's disease. Aliment Pharmacol Trier 1987;1:39-43.
12. Peltekian KM, Williams CN, MacDonald AS, et al. Open trial of cyclosporine in patients with severe active Crohn's disease refractory to conventional therapy. Can J Gastroenterol 1988;2:5-11.
13. Parrot NR, Taylor RMR, Venables CW, et al. Treatment of Crohn's disease in relapse with cyclosporin A. Br J Surg 1988;75:1185-8.
14. Fukushima T, Sugita A, Masuzawa S, et al. Effects of cyclosporin A on active Crohn's disease. Gastroenterol Jpn 1989;24:12-5.
15. Brynskov J, Binder V, Riis P, et al. Low-dose cyclosporin for Crohn's disease: Implications for clinical trials. Aliment Pharmacol Ther 1989; 3:135-42.
16. Stange EF, Fleig WE, Rehklau E, et al. Cyclosporin A treatment in inflammatory bowel disease. Dig Dis Sci 1989;34:1387-92.
17. Baker K, Jewell DP. Cyclosporin for the treatment of severe inflammatory bowel disease. Aliment Pharmacol Ther 1989;3:143-9.
18. Lofberg R, Angelin B, Einarsson K, et al. Unsatisfactory effect of cyclosporin A treatment in Crohn's disease. A report of five cases. J Intern Med 1989;226:157-61.
19. Ardizzone S, Fasoli R, Sangaletti O, et al. The treatment of chronically active Crohn's disease with cyclosporin A. Curr Ther Res 1990;48: 1-4.
20. Ranzi T, Campanini MC, Quarto Di Palo F, et al. Cyclosporin A in Crohn's disease. Curr Ther Res 1989;45:245-52.
21. Lichtiger S. Cyclosporine therapy in inflammatory bowel disease: Open-label experience. Mt Sinai J Med 1990;57:315-9.
22. Lobo AJ, Juby LD, Rothwell J, et al. Long-term treatment of Crohn's disease with cyclosporine. The effect of a very low dose on maintenance of remission. J Clin Gastroenterol 1991;13:42-5.
23. Hanaeur SB, Smith MB. Rapid closure of Crohn's disease fistulas with intravenous cyclosporin A. Am J Gastroenterol 1993;88:646-9.
24. Actis GC, Ponti V, Pera A, et al. Colectomy avoided in ulcerative colitis (UC) with low dose intravenous (IV) cyclosporin (CYA) and prednisone tapering. Gastroenterology 1992;102:A588.
25. Markowitz J. Cyclosporine lacks therapeutic efficacy in highly destructive perianal Crohn's disease associated with Crohn's disease (CD). Am J Gastroenterol 1993;88:1620.
26. Ramakrishna J, Langhans N, Calenda K, et al. Combined use of cyclosporin A (CSA) and azathioprine (AZA) in pediatric inflammatory bowel disease (IBD). Gastroenterology 1994;106:A23.
27. Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula in Crohn's disease. Dig Dis Sci 1994;39:374-80.
28. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330:1841-5.
29. Sandborn WJ. A critical review of cyclosporine therapy in inflammatory bowel disease. Inflammatory Bowel Dis 1995;1:48-63.
30. Sandborn WJ, Lawson GM, Krom RAF, et al. Hepatic allograft cyclosporine concentration is independent of the route of cyclosporine administration and correlates with the occurrence of early cellular rejection. Hepatology 1992;15:1086-91.
31. Hanas E, Tufveson G, Lindgren P-G, et al. Concentrations of cyclosporine-A metabolites in transplanted human kidney tissue during rejection and stable graft function. Clin Transplant 1991;5:107-11.
32. Sandborn WJ, Strong RM, Forland SC, et al. The pharmacokinetics and colonic tissue concentrations of cyclosporine after iv oral and enema administration. J Clin Pharmacol 1991;31:76-80.
33. Sandborn WJ, Tremaine WJ, Schroeder KW, Steiner et al. Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis. Am J Gastroenterol 1993;88:640-5.
34. Sandborn WJ, Tremaine WJ, Schroeder KW, et al. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 1994;106:1429-35.
35. Sandborn WJ, Goldman DH, Lawson GM, et al. Measurement of colonic tissue cyclosporine concentration in children with severe ulcerative colitis. J Pediatr Gastroenterol Nutr 1992;15:125-9.
36. Best WR, Becktel JN, Singleton JW, et al. Development of a Crohn's disease activity index. Gastroenterology 1976;77:339-44.
37. Best WR, Becktel JN, Singleton JW. Rederived values of the eight coefficients of the Crohn's disease activity index (CDAI). Gastroenterology 1979;77:843-6.
38. Moyer TP, Charlson JR, Ebnet LE. Improved chromatography of cyclosporine. Ther Drug Monit 1986;8:466-8.
39. Moyer TP, Johnson P, Faynor SM, et al. Cyclosporine: A review of drug monitoring problems and presentation of a simple, accurate liquid chromatographic procedure that solves these problems. Clin Biochem 1986;19:83-9.
40. Modigliani R, Mary JY. Group d'etudes therapeutiques des affections inflammatoires du tube digestif (GETAID). Reproducibility of colonoscopic findings in Crohn's disease. A prospective multicenter study of interobserver variation. Dig Dis Sci 1987;32:1370-9.
41. Mary JY, Modigliani R. Group d'études therapeutiques des affections inflammatoires du tube digestif (GETAID). Development and validation of an endoscopic index of the severity for Crohn's disease. A prospective multicentre study. Gut 1989;30:983-9.
42. Modigliani R, Mary JY, Simon JF, et al. Group d'etude therapeutique des affections inflammatoires digestives. Clinical, biological and endoscopic picture of attacks of Crohn's disease. Evolution on prednisone. Gastroenterology 1990;98:811-8.
43. Sigman EM, Elwood CM, Knox F. The measurement of glomerular filtration rate in man with sodium iothalamate 1211 (Conray). J Nucl Med 1966;7:60-8.
44. Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989;110:353-6.
45. Beveridge T, Gratwphl A, Michot F, et al. Cyclosporin A: Pharmacokinetics after a single dose in man and serum levels after multiple doses in recipients of allogenic bone marrow grafts. Curr Ther Res 1981;30: 5-18.
46. Tegzess AM, Doorenbos BM, Minderhound JM, et al. Prospective serial renal function studies in patients with nonrenal disease treated with cyclosporine A. Transplant Proc 1988;20(suppl 2):390-3.
47. Ross EA, Wilkinson A, Hawkins RA, et al. The plasma creatinine is not an accurate reflection of the glomerular filtration rate in stable renal transplant patients receiving cyclosporine. Am J Kidney Dis 1987;10: 113-7.
48. Feutren G, Mihatsch MJ, for the International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. N Engl J Med 1992;326:1654-60.
49. Brynskov J, Thomsen H, Nielson SL. Renographic monitoring of renal function in patients with Crohn's disease treated with low-dose cyclosporin: A controlled study. Br Med J 1990;300:1438-9.
50. Lobo AJ, Juby LD, Smith AH, et al. Effect of oral cyclosporine on renal function in Crohn's disease. Dig Dis Sci 1993;38:1624-30.